BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 34362508)

  • 1. Co-occurrence of
    Zanelli M; Bisagni A; Sanguedolce F; Broggi G; Fragliasso V; Zizzo M; Palicelli A; Martino G; Cresta C; Caprera C; Corsi M; Gentile P; Gozzi F; Trombetta D; Parente P; Caltabiano R; Koufopoulos N; Cimino L; Cavazza A; Fraternali Orcioni G; Ascani S
    Front Oncol; 2023; 13():1329298. PubMed ID: 38282677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic myeloproliferative neoplasms with concomitant
    Zanelli M; Fragliasso V; Loscocco GG; Sanguedolce F; Broggi G; Zizzo M; Palicelli A; Ricci S; Ambrogi E; Martino G; Aversa S; Coppa F; Gentile P; Gozzi F; Caltabiano R; Koufopoulos N; Asaturova A; Cimino L; Cavazza A; Orcioni GF; Ascani S
    Front Cell Dev Biol; 2024; 12():1391078. PubMed ID: 38596359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression of myeloproliferative neoplasm with BCR::JAK2 fusion to acute leukemia of ambiguous lineage.
    Suárez EU; Piris MÁ; Rodríguez-Pinilla SM; García JF; López-Lorenzo JL; Cornago-Navascués J; Salgado-Sánchez R; Castaño-Bonilla T; Mata-Serna R; Alonso-Domínguez JM; Llamas P
    Ann Hematol; 2024 May; 103(5):1797-1799. PubMed ID: 38308706
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives.
    Krecak I; Verstovsek S; Lucijanic M
    Ann Hematol; 2024 May; 103(5):1513-1523. PubMed ID: 37665349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Distribution of ETV6-ABL Fusion Gene in Hematopoietic Cell Populations of Myeloproliferative Neoplasm].
    Chen Y; Liu Q; Li Y; Wei H; Rao Q; Wang M; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1242-1246. PubMed ID: 34362509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR-ABL- and JAK2V617F-Positive MPN.
    Tillmann S; Olschok K; Schröder SK; Bütow M; Baumeister J; Kalmer M; Preußger V; Weinbergerova B; Kricheldorf K; Mayer J; Kubesova B; Racil Z; Wessiepe M; Eschweiler J; Isfort S; Brümmendorf TH; Becker W; Schemionek M; Weiskirchen R; Koschmieder S; Chatain N
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Tyrosine Kinase-Driven Networks of Novel Long Non-coding RNAs and Their Molecular Targets in Myeloproliferative Neoplasms.
    Wong NK; Luo S; Chow EYD; Meng F; Adesanya A; Sun J; Ma HMH; Jin W; Li WC; Yip SP; Huang CL
    Front Cell Dev Biol; 2021; 9():643043. PubMed ID: 34414175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AXL Inhibition Represents a Novel Therapeutic Approach in
    Beitzen-Heineke A; Berenbrok N; Waizenegger J; Paesler S; Gensch V; Udonta F; Vargas Delgado ME; Engelmann J; Hoffmann F; Schafhausen P; von Amsberg G; Riecken K; Beumer N; Imbusch CD; Lorens J; Fischer T; Pantel K; Bokemeyer C; Ben-Batalla I; Loges S
    Hemasphere; 2021 Sep; 5(9):e630. PubMed ID: 34396051
    [No Abstract]   [Full Text] [Related]  

  • 9. TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis.
    Varricchio L; Iancu-Rubin C; Upadhyaya B; Zingariello M; Martelli F; Verachi P; Clementelli C; Denis JF; Rahman AH; Tremblay G; Mascarenhas J; Mesa RA; O'Connor-McCourt M; Migliaccio AR; Hoffman R
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34383713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas12a-Based Ultrasensitive and Rapid Detection of
    Chen M; Zhang C; Hu Z; Li Z; Li M; Wu L; Zhou M; Liang D
    Biosensors (Basel); 2021 Jul; 11(8):. PubMed ID: 34436049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients.
    Loscocco GG; Guglielmelli P; Gangat N; Rossi E; Mannarelli C; Betti S; Maccari C; Ramundo F; Jadoon Y; Gesullo F; Ceglie S; Paoli C; Pardanani A; De Stefano V; Tefferi A; Vannucchi AM
    Am J Hematol; 2021 Nov; 96(11):1472-1480. PubMed ID: 34424575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
    Dam MJB; Pedersen RK; Knudsen TA; Andersen M; Skov V; Kjaer L; Hasselbalch HC; Ottesen JT
    Eur J Haematol; 2021 Dec; 107(6):624-633. PubMed ID: 34411333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The requirement for pyruvate dehydrogenase in leukemogenesis depends on cell lineage.
    Jun S; Mahesula S; Mathews TP; Martin-Sandoval MS; Zhao Z; Piskounova E; Agathocleous M
    Cell Metab; 2021 Sep; 33(9):1777-1792.e8. PubMed ID: 34375613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proposal and clinical application of molecular genetic risk scoring system, "MRplus", for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre.
    Gupta SK; Bakhshi S; Kamal VK; Gupta R; Sharma P; Pushpam D; Sahoo RK; Sharma A
    Leuk Res; 2021 Dec; 111():106683. PubMed ID: 34371436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukemia associated RUNX1T1 gene reduced proliferation and invasiveness of glioblastoma cells.
    Kumar P; Verma V; Mohania D; Gupta S; Babbar AK; Rathi B; Dhanda RS; Yadav M
    J Cell Biochem; 2021 Nov; 122(11):1737-1748. PubMed ID: 34369622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.
    Lewis R; Maurer HC; Singh N; Gonzalez-Menendez I; Wirth M; Schick M; Zhang L; Isaakidis K; Scherger AK; Schulze V; Lu J; Zenz T; Steiger K; Rad R; Quintanilla-Martinez L; Espeli M; Balabanian K; Keller U; Habringer S
    Leukemia; 2021 Oct; 35(10):2895-2905. PubMed ID: 34363012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Investigation of Laboratory and Clinical Feature in the Patients with Myeloproliferative Neoplasm Co-expression of BCR-ABL1 and JAK2 V617F].
    Yuan XG; Wan RT; Zhao XW; Yang XZ; Xiao J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1236-1241. PubMed ID: 34362508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of Clinical Characteristics of JAK2 V617F and BCR-ABL Double-Mutant Myeloproliferative Neoplasms].
    Yan J; Ding YW; Wang PY; Wu YP; Zhang HC; Liu LH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1540-1547. PubMed ID: 34627437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.
    Soderquist CR; Ewalt MD; Czuchlewski DR; Geyer JT; Rogers HJ; Hsi ED; Wang SA; Bueso-Ramos CE; Orazi A; Arber DA; Hexner EO; Babushok DV; Bagg A
    Mod Pathol; 2018 May; 31(5):690-704. PubMed ID: 29327708
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.